HCQS 200mg Tablet

HCQS 200mg Tablet is a prescription based medicine with Hydroxychloroquine (200mg) as an active ingredient. It is used in the treatment of autoimmune conditions like rheumatoid arthritis and systemic lupus erythematosus. It can also be used to treat patients with type 2 diabetes mellitus to improve glycemic control. It works by slowing the disease's progression and relieves pain, swelling, and redness. It should be taken with food at the same time each day to get effective results. Don't take more than the recommended dose.

• Rheumatoid arthritis
• Systemic lupus erythematosus (SLE)

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the HCQS 200mg Tablet   can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:

• Skin rash
• Itching
• Affect lability
• Abdominal pain
• Blurred vision
• Headache
• Decreased appetite
• Diarrhea
• Vomiting
• Nausea

Seek medical attention in case of any unusual or severe side effects immediately.

• Take HCQS 200mg Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.
  
  

• A disease-modifying anti-rheumatoid medication (DMARD) is HCQS 200 Tablet with Hydroxychloroquine (200mg) as an active ingredient. It acts by decreasing the immune system's overactive activity, which results in joint pain and swelling.
• As a result, the underlying medical condition progresses more slowly. In addition, it has been believed that hydroxychloroquine can improve beta-cell activity and insulin sensitivity, improving glycemic management for individuals with type 2 diabetes mellitus.
  

• Marmor, M. F., Ahn, S. J., Ehlers, J. P., Melles, R. B., Mieler, W. F., Sarraf, D., & Yusuf, I. H. (2025). Special Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2026 Revision).Ophthalmology. https://www.researchgate.net/publication/397598533_Special_Report_Recommendations_on_Screening_for_Hydroxychloroquine_Retinopathy_2026_Revision
• Chopra, A., Saluja, M., Tillu, G., Venugopalan, A., Narsimulu, G., Handa, R., ... & Patwardhan, B. (2012). Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study. Clinical rheumatology, 31(2), 259-269. https://pubmed.ncbi.nlm.nih.gov/21773714/
• Tett, S. E., Cutler, D. J., Day, R. O., & Brown, K. F. (1989). Bioavailability of hydroxychloroquine tablets in healthy volunteers. British journal of clinical pharmacology, 27(6), 771-779. https://pubmed.ncbi.nlm.nih.gov/2757893/
• Mehta, P., Situ, B. A., Wise, L. M., Savvas, S., Daskivich, L. P., & Toy, B. C. (2023). Mitigating hydroxychloroquine toxicity with a clinical decision support tool. Ophthalmology, 130(8), 874-876. https://pubmed.ncbi.nlm.nih.gov/37105380/
• Das, S. K., Pareek, A., Mathur, D. S., Wanchu, A., Srivastava, R., Agarwal, G. G., & Chauhan, R. S. (2007). Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial–an Indian experience. Current medical research and opinion, 23(9), 2227-2234. https://pubmed.ncbi.nlm.nih.gov/17692155/